Pila Pharma AB (publ) (PILA.ST)
SEK 3.46
(13.44%)
SEK 3.46
(13.44%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -6.39 Million SEK | 28.09% |
| 2022 | -8.89 Million SEK | 4.0% |
| 2021 | -9.26 Million SEK | -174.03% |
| 2020 | -3.37 Million SEK | 28.37% |
| 2019 | -4.71 Million SEK | 4.69% |
| 2018 | -4.95 Million SEK | -3.28% |
| 2017 | -4.79 Million SEK | -226.29% |
| 2016 | -1.46 Million SEK | -63.23% |
| 2015 | -899.85 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.04 Million SEK | 0.0% |
| 2024 Q1 | -2.04 Million SEK | -60.24% |
| 2023 Q2 | -1.75 Million SEK | 4.72% |
| 2023 Q4 | -1.27 Million SEK | 16.07% |
| 2023 Q1 | -1.84 Million SEK | 93.41% |
| 2023 Q3 | -1.51 Million SEK | 13.6% |
| 2023 FY | -6.39 Million SEK | 28.09% |
| 2022 Q4 | -27.96 Million SEK | -4395.25% |
| 2022 Q2 | -2.25 Million SEK | 6.37% |
| 2022 FY | -8.89 Million SEK | 4.0% |
| 2022 Q1 | -2.4 Million SEK | 22.0% |
| 2022 Q3 | 651 Thousand SEK | 128.93% |
| 2021 Q1 | -2.46 Million SEK | -51.94% |
| 2021 FY | -9.26 Million SEK | -174.03% |
| 2021 Q4 | -3.08 Million SEK | 2.94% |
| 2021 Q3 | -3.17 Million SEK | -99.0% |
| 2021 Q2 | -1.59 Million SEK | 35.22% |
| 2020 Q3 | -294 Thousand SEK | 0.0% |
| 2020 FY | -3.37 Million SEK | 28.37% |
| 2020 Q4 | -1.62 Million SEK | -451.15% |
| 2019 FY | -4.71 Million SEK | 4.69% |
| 2018 FY | -4.95 Million SEK | -3.28% |
| 2017 FY | -4.79 Million SEK | -226.29% |
| 2016 FY | -1.46 Million SEK | -63.23% |
| 2015 FY | -899.85 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.52 Million SEK | 61.305% |
| Amniotics AB (publ) | -29.07 Million SEK | 78.01% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | 56.33% |
| BioArctic AB (publ) | 252.64 Million SEK | 102.531% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 98.337% |
| Saniona AB (publ) | -81.06 Million SEK | 92.113% |
| Simris Alg AB (publ) | -36.63 Million SEK | 82.549% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 98.011% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 68.254% |
| NextCell Pharma AB | -43.17 Million SEK | 85.191% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 62.604% |
| AcouSort AB (publ) | -17.48 Million SEK | 63.44% |
| Active Biotech AB (publ) | -46.48 Million SEK | 86.246% |
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 97.432% |
| Camurus AB (publ) | 532.35 Million SEK | 101.201% |
| Cantargia AB (publ) | -290.01 Million SEK | 97.796% |
| Genovis AB (publ.) | 54.22 Million SEK | 111.79% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 94.444% |
| Mendus AB (publ) | -100.65 Million SEK | 93.648% |
| Kancera AB (publ) | -65.04 Million SEK | 90.171% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -82.404% |
| LIDDS AB (publ) | -40.67 Million SEK | 84.282% |
| Lipum AB (publ) | -37.25 Million SEK | 82.839% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | 48.321% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 135.5% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 61.019% |
| OncoZenge AB (publ) | -15.9 Million SEK | 59.796% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 97.94% |
| Xintela AB (publ) | -57.23 Million SEK | 88.83% |
| Ziccum AB (publ) | -21.56 Million SEK | 70.347% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 84.662% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 96.463% |
| CombiGene AB (publ) | -36.3 Million SEK | 82.39% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 95.638% |
| Intervacc AB (publ) | -93.57 Million SEK | 93.168% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -656.598% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | 58.785% |
| Corline Biomedical AB | -1.78 Million SEK | -257.564% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 96.463% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 88.463% |
| Aptahem AB (publ) | -10.1 Million SEK | 36.73% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 95.251% |
| Fluicell AB (publ) | -26.87 Million SEK | 76.215% |
| Biovica International AB (publ) | -126.07 Million SEK | 94.929% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 84.959% |
| Abliva AB (publ) | -96.54 Million SEK | 93.378% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 98.032% |
| 2cureX AB (publ) | -36.36 Million SEK | 82.418% |
| I-Tech AB | 24.43 Million SEK | 126.164% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 99.189% |
| Cyxone AB (publ) | -21.66 Million SEK | 70.485% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 93.967% |
| Biosergen AB | -27.26 Million SEK | 76.551% |
| Nanologica AB (publ) | -69.96 Million SEK | 90.862% |
| SynAct Pharma AB | -224.49 Million SEK | 97.152% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 85.528% |
| BioInvent International AB (publ) | -369.94 Million SEK | 98.272% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 73.311% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 97.477% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 94.236% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | 44.724% |